CV Therapeutics regains rights to Ranexa. (Monday, July 14).(Brief Article)

CV Therapeutics Inc. renegotiated with partner Innovex Inc. for a return of all rights associated with the chronic angina candidate Ranexa. In exchange for commercialization rights, including the opportunity to hire and train a sales force, CV Therapeutics has agreed to issue Innovex, a subsidiary of Research Triangle Park, N.C.-based Quintiles Transnational Corp., …